Big risers include Eli Lilly, Biogen, Moderna and Biontech.
And four other potential targets that could make sense for the beleaguered group.
And Lilly was well ahead of the pack, fuelled by Alzheimer’s hopes.
Long-awaited results from the Herald study are a bust, and the data will likely deteriorate further.
But with many Western markets already saturated, it is worth wondering how important Novavax’s Covid-19 jab will become.
Instead of long-awaited phase 3 data Novavax’s first-quarter presentation reveals a Covid-19 vaccine manufacturing snafu.